Most stocks with high dividend yields are clustered in defensive parts of the stock market, where growth rates are lower. Yet at BB Biotech we offer a 5% dividend yield by focusing on future-oriented markets with strong growth prospects. Subject to shareholder approval, a dividend of CHF 2.75 per share will be paid in March 2017.
Biotech stocks had to contend with multiple challenges in 2016 but despite a year of uncertain political activity, the sector's fundamentals have remained solid. New regulatory approvals of biotech drugs, successful clinical trials, and ongoing takeover activity suggest the sector will continue to deliver double-digit growth in the future.
An ageing global population will also keep the rate of healthcare spending in industrialised and emerging market countries at a higher level than the corresponding rate of GDP expansion. And it should be noted that the industry still serves as the engine of innovation in new drug development. Investors can effectively capture this structural growth potential by investing with BB Biotech.
With European bond yields still at rock bottom, high-yielding stocks are clearly a better alternative than investments in fixed income. Against this backdrop, the mix of fundamental growth and sustainable dividend income that BB Biotech offers will remain an effective tool for generating sustained value in investor portfolios.
For more information, please contact:
Claude Mikkelsen
[email protected], +44 203 770 67 85 , www.bbbiotech.com
Disclaimer
All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.
